UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC. 20549

SCHEDULE 14A (Rule 14A-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

iled	l by the Registrant x l by a Party other than the Registrant k the appropriate box:					
]	Preliminary Proxy Statement		Confidential, for Use of the Commission Only			
]	Definitive Proxy Statement		(as permitted by Rule 14a-6(e)(2))			
X	Definitive Additional Materials					
]	Soliciting Material Pursuant to Rule 14a-11(c)or Rule 14a-12					
	LEX	CICON PHARMACEUT	ICALS, INC.			
	(Na	me of Registrant as Specified	In Its Charter)			
	(Name of Person	(s) Filing Proxy Statement, if	Other Than the Registrant)			
	-	ent of Filing Fee (Check the a	ppropriate box):			
X	No fee required.					
_						
J	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0	-11.				
	(1) Title of each class of securities to which transaction applies:	N/A				
	(2) Aggregate number of securities to which transaction applies:	Aggregate number of securities to which transaction applies: N/A				
	(3) Per unit price or other underlying value of transaction compu was determined): N/A	ted pursuant to Exchange Ac	Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it			
	(4) Proposed maximum aggregate value of transaction: N/A					
	(5) Total fee paid: \$0Fee paid previously with preliminary materials: N/A					
		v Evchange Act Rule 0-11(a)	2) and identify the filing for which the offsetting fee was paid previously. Identify			
	Check box if any part of the fee is offset as provided by the previous filing by registration statement number, or					
	(1) Amount Previously Paid:					
	 Amount Previously Paid: Form, Schedule or Registration Statement No.: 					
	(3) Filing Party:					
	(4) Date Filed					



LEXICON PHARMACEUTICALS, INC.

2023 Annual Meeting Vote by April 26, 2023 11:59 PM ET

LEXICON PHARMACEUTICALS, INC. 2445 TECHNOLOGY FOREST BLVD., 11th FLOOR THE WOODLANDS, TX 77381



You invested in LEXICON PHARMACEUTICALS, INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on April 27, 2023.

Get informed before you vote

View the Notice & Proxy Statement, Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 13, 2023. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number





Vote in Person at the Meeting*

April 27, 2023 8:00 AM CDT

Embassy Suites by Hilton The Woodlands at Hughes Landing 1855 Hughes Landing Blvd The Woodlands, TX 77380

^{*}Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.

	ing Items	Recommend		
1.	Election of Directors Nominees: 01) Samuel L. Barker, Ph.D. 02) Christopher J. Sobecki 03) Judith L. Swain, M.D.	⊘ For		
2.	Ratification and approval of the amendment to the Company's 2017 Equity Incentive Plan			
	Ratification and approval of the amendment to the Company's 2017 Non-Employee Directors' Equity Incentive Plan			
1.	Advisory vote to approve the compensation paid to the Company's named executive officers			
j.	Advisory vote to determine the frequency of future advisory votes on the compensation paid to the Company's named executive officers			
5.	Ratification and approval of the appointment of Ernst & Young LLP as the Company's independent auditors f fiscal year ending December 31, 2023			

NOTE: In their discretion, upon such other matters that may properly come before the meeting or any adjournment or adjournment thereof.

 $Prefer to \ receive \ an \ email \ instead? \ While \ voting \ on \ www. Proxy Vote. com, \ be \ sure \ to \ click \ "Sign \ up \ for \ E-delivery".$